United States Patent 6,703,418: Scope, Claims, Expiration, and Dronabinol Patent Landscape

U.S. Patent No. 6,703,418 covered the use of delta-9-tetrahydrocannabinol, including dronabinol, to stimulate weight gain in patients with symptomatic HIV infection. Its dependent claims addressed oral administration, capsules in sesame oil, alternative dosage forms, antiviral therapy, dosing from 2.5 mg to 20 mg per day, and once-daily, twice-daily, or single-dose administration.

The patent issued on March 9, 2004, and its enforceable term ended in approximately 2020 based on the patent’s nonprovisional filing date and standard 20-year patent-term rules. It therefore does not currently block generic dronabinol products, HIV-wasting therapies, or competing formulations.

What does U.S. Patent 6,703,418 protect?

The patent protects a treatment method with four essential elements:

The patient has symptomatic HIV infection.
The patient receives a pharmaceutical composition containing delta-9-tetrahydrocannabinol.
The amount administered is sufficient to cause increased patient weight.
The treatment is directed to stimulating weight gain.

Independent claim 1 is the central claim:

A method of treating a patient with symptomatic HIV infection to stimulate weight gain by administering a pharmaceutical composition comprising delta-9-tetrahydrocannabinol in an amount sufficient to cause an increase in weight.

The patent is therefore a method-of-use patent, not primarily a compound, composition-of-matter, manufacturing, or delivery-device patent.

Patent identification and timeline

Item	Detail
Patent	U.S. Patent No. 6,703,418
Title	Use of tetrahydrocannabinol in the treatment of HIV wasting syndrome
Patent type	Utility patent; therapeutic method
Issue date	March 9, 2004
Patent holder at issuance	Unimed Pharmaceuticals, Inc.
Active ingredient	Delta-9-tetrahydrocannabinol
Pharmaceutical form	Broadly defined; includes oral and nonoral dosage forms
Principal disease	Symptomatic HIV infection
Principal therapeutic result	Increased patient weight
Estimated statutory expiration	Approximately 2020
Current status	Expired; no current exclusionary patent rights

The patent’s commercial context is Marinol, the dronabinol product developed and marketed by Unimed and later associated with Solvay, Abbott, and AbbVie. The patent should be analyzed separately from patents covering dronabinol itself, capsule formulations, manufacturing processes, or other indications.

How broad is claim 1 of Patent 6,703,418?

Claim 1 is broad in formulation and route but narrow in disease context and therapeutic purpose.

Broad elements

The claim does not require:

Dronabinol specifically, because it covers delta-9-tetrahydrocannabinol generally.
A particular dosage form.
Oral administration.
A specific dose.
A particular frequency of administration.
Concomitant antiviral therapy.
A particular weight-gain threshold.
A particular pharmaceutical excipient.

The phrase “pharmaceutical composition comprising delta-9-tetrahydrocannabinol” could encompass capsules, tablets, inhaled formulations, injectable formulations, transdermal products, sublingual products, and suppositories, subject to the limitations in the dependent claims and ordinary claim-construction principles.

Narrow elements

Claim 1 requires a specific clinical population and treatment objective:

The patient must have symptomatic HIV infection.
The purpose must be to stimulate weight gain.
The dose must be sufficient to cause an increase in weight.

A product used for chemotherapy-induced nausea, appetite loss unrelated to HIV, chronic pain, multiple sclerosis, or another cannabinoid indication would not inherently practice claim 1 merely because it contains dronabinol.

A product prescribed to a patient with HIV for appetite stimulation may present a stronger infringement case, particularly if the product labeling, prescribing information, promotional materials, or treatment protocol identifies weight gain or HIV-associated wasting as the purpose.

What do the dependent claims add?

The dependent claims divide into route, dosage form, patient-treatment context, active-ingredient identity, and dosing limitations.

Claims	Added limitation	Commercial significance
2	Oral administration	Targets oral dronabinol products
3	Capsules containing THC in sesame oil	Closely aligned with Marinol-type soft-gel capsule technology
4	Intranasal, inhalant, parenteral, transdermal, or related formulations	Broadens coverage across nontraditional dosage forms
5	Tablet, capsule, inhalant, injectable, transdermal, sublingual, or suppository	Expressly identifies multiple dosage-form categories
6	Inhalant dosage form	Covers inhaled delivery
7	Oral administration of the inhalant	Covers oral inhalation
8	Soft gelatin capsule	Narrows capsule coverage
9	Administration during antiviral therapy	Links treatment to HIV treatment context
10	THC is dronabinol	Identifies the pharmaceutical form used in Marinol
11	Oral, intranasal, inhaled, injected, transdermal, or sublingual route	Broad route limitation
12	Inhalation is oral inhalation	Further narrows inhalation
13	Approximately 2.5 mg to 20 mg per day	Defined daily-dose range
14	Approximately 2.5 mg per day	Low-dose species
15	Once-daily administration	Frequency limitation
16	Twice-daily administration	Frequency limitation
17	Single-dose administration	Single-administration limitation

Claims 4 and 5 are particularly expansive on paper, but their practical value depends on whether the specified dosage forms were adequately supported by the specification and whether the claims survived examination without narrowing amendments. Because the patent is expired, these issues now matter mainly for historical validity analysis, freedom-to-operate records, and prosecution strategy.

What formulations are protected by Patent 6,703,418?

The formulation coverage is primarily use-based. The patent does not necessarily give the owner a standalone right to every listed formulation. It covers use of those formulations in the claimed HIV weight-gain method.

Sesame-oil capsules

Claim 3 requires capsules containing delta-9-tetrahydrocannabinol in sesame oil. This limitation tracks the formulation architecture historically associated with Marinol soft gelatin capsules.

The claim is narrower than claim 1 because it requires:

A capsule;
THC in sesame oil; and
Use in a symptomatic HIV patient to stimulate weight gain.

A generic dronabinol capsule using sesame oil could have fallen within claim 3 during the patent term if it was marketed or used for the claimed indication. The claim would not necessarily cover the same capsule when used solely for chemotherapy-related nausea and vomiting.

Soft gelatin capsules

Claim 8 further limits the capsule to a soft gelatin dosage form. This is a formulation and presentation limitation, not a separate composition-of-matter claim.

A hard-shell capsule, tablet, oral solution, or sublingual formulation would not meet claim 8, although it could still implicate broader claims if the remaining requirements were satisfied.

Nonoral dosage forms

Claims 4, 5, and 11 identify:

Intranasal solutions or suspensions;
Inhalant solutions or suspensions;
Parenteral solutions or suspensions;
Transdermal patches;
Transdermal gels;
Transdermal creams;
Tablets;
Injectables;
Sublingual products; and
Suppositories.

These claims attempted to create a broad use patent covering alternative cannabinoid delivery routes. Their commercial importance was limited by the absence of widespread FDA-approved dronabinol products in many of those forms.

Does the patent cover Marinol or dronabinol?

Yes, the claims expressly reach dronabinol use in the claimed HIV weight-gain setting.

Claim 10 states that the delta-9-tetrahydrocannabinol is dronabinol. Marinol contains dronabinol, the synthetic form of delta-9-tetrahydrocannabinol used in FDA-approved products.

The patent does not, however, provide a perpetual monopoly over:

Dronabinol as a chemical compound;
All dronabinol products;
All Marinol indications;
All cannabinoid appetite-stimulation uses; or
All HIV treatments involving weight change.

Its protection depends on the claimed patient population, therapeutic objective, administration, dosage form, and dose limitations.

What is the FDA and Orange Book status of the covered product?

Dronabinol has FDA-approved uses that include:

Treatment of anorexia associated with weight loss in patients with AIDS; and
Treatment of nausea and vomiting associated with cancer chemotherapy in patients who have failed adequate conventional antiemetic treatment.

Marinol is associated with FDA New Drug Application 018651. FDA-approved generic dronabinol products have entered the market through the abbreviated new drug application pathway. Syndros, an oral solution containing dronabinol, is a separate FDA-approved product.

Product	Active ingredient	Dosage form	Regulatory pathway
Marinol	Dronabinol	Soft gelatin capsule	NDA
Generic dronabinol capsules	Dronabinol	Capsule	ANDA
Syndros	Dronabinol	Oral solution	NDA
Cesamet	Nabilone	Capsule	NDA; different cannabinoid

The FDA Orange Book is relevant to product-specific patents and regulatory exclusivity, but Patent 6,703,418 no longer creates a current barrier to ANDA approval or commercial launch because its patent term has ended. Orange Book listing and patent enforceability are distinct issues. A patent may once have been listed against a drug product and later become expired.

When did Patent 6,703,418 lose exclusivity?

The patent lost enforceable exclusivity at the end of its statutory term, approximately in 2020.

Exclusivity timeline

Event	Approximate date
Nonprovisional patent filing	2000
Patent issuance	March 9, 2004
FDA-era commercial relevance	2000s and 2010s
Expected 20-year patent term endpoint	2020
Current status	Expired

Patent expiration eliminates the right to exclude others under the patent. It does not erase the historical patent, invalidate prior infringement claims, or eliminate other patents that may have covered particular products or formulations.

FDA regulatory exclusivity, where applicable, is separate from patent term. The patent’s expiration does not itself determine whether a drug had five-year, three-year, orphan-drug, pediatric, or other FDA exclusivity.

Were there Paragraph IV challenges to this patent?

A Paragraph IV certification is an ANDA applicant’s assertion that a listed patent is invalid, unenforceable, or will not be infringed.

Because Patent 6,703,418 is expired, a current applicant does not need to rely on a Paragraph IV certification to launch a product against this patent. The patent may have been relevant to earlier generic-drug certifications, but the claims supplied do not establish a specific Paragraph IV notice letter, district-court case, settlement, or launch date.

The practical result is clear: no current Paragraph IV challenge is required to overcome an expired patent.

What litigation and settlement issues affect the patent?

The patent could historically have supported infringement allegations against a company that:

Sold dronabinol for HIV-associated anorexia or wasting;
Promoted dronabinol to stimulate weight gain in symptomatic HIV patients;
Marketed a capsule containing dronabinol in sesame oil for that use; or
Used a claimed daily dose or administration schedule.

The most relevant legal theories would have been:

Direct infringement under 35 U.S.C. § 271(a);
Induced infringement under 35 U.S.C. § 271(b);
Contributory infringement under 35 U.S.C. § 271(c);
Invalidity based on anticipation or obviousness;
Written-description or enablement challenges;
Indefiniteness challenges involving “amount sufficient to cause an increase in weight.”

No current infringement risk remains from this patent alone. A historical settlement involving Patent 6,703,418 would not revive the expired patent or prevent later market entry unless separate contractual restrictions applied.

How strong were the claims?

Strengths

Claim 1 had commercially meaningful breadth because it covered any pharmaceutical composition containing delta-9-THC, regardless of route or dosage form, when used for HIV-related weight gain.

Claim 10 strengthened product-specific relevance by expressly identifying dronabinol. Claims 13 through 17 added practical dosing configurations that could correspond to real-world prescriptions.

The HIV-specific limitation also aligned with the FDA-approved dronabinol indication for anorexia associated with weight loss in AIDS patients.

Vulnerabilities

The claims presented several potential validity and enforcement weaknesses.

First, dronabinol had already been used medically before the patent’s filing. Earlier disclosure of appetite stimulation, AIDS-related weight loss, or cannabinoid treatment could have supported anticipation or obviousness arguments.

Second, the phrase “in an amount sufficient to cause an increase in weight” is outcome-oriented. It may create proof questions because individual patient responses vary, and the claim does not state a minimum weight increase.

Third, many dependent claims recite broad lists of dosage forms and routes. A challenger could have examined whether the specification adequately enabled the full range, particularly transdermal, intranasal, parenteral, suppository, and inhaled forms.

Fourth, some claim relationships create drafting ambiguity. Claim 7, for example, states that an inhalant is administered orally, while claim 12 similarly narrows inhalation to oral inhalation. Those provisions may have raised claim-construction issues but do not affect the present expired status.

Which companies compete in the dronabinol market?

The relevant competitive groups include:

AbbVie and predecessor companies associated with Marinol;
Generic manufacturers of dronabinol capsules;
Insys Therapeutics, historically associated with Syndros;
Nabilone manufacturers selling Cesamet, a chemically different cannabinoid;
Compounded-cannabinoid suppliers, subject to applicable federal and state law;
Cannabis-derived and synthetic cannabinoid developers pursuing non-FDA-approved markets.

Dronabinol and nabilone are not interchangeable for patent analysis. Nabilone is a distinct synthetic cannabinoid and would not satisfy a claim requiring delta-9-tetrahydrocannabinol or dronabinol.

Is there biosimilar risk?

No conventional biosimilar pathway applies. Dronabinol is a small-molecule active ingredient, not a biologic subject to the Biologics Price Competition and Innovation Act.

The relevant competitive pathway is an ANDA for a generic drug product, together with any applicable 505(b)(2) pathway for a product with differences in formulation, route, dosing, or clinical use.

What generic launch risks remain?

Patent 6,703,418 creates no current generic launch barrier. Remaining risks would arise from separate sources:

Later-expiring formulation patents;
Product-specific Orange Book patents;
Trade-secret manufacturing processes;
Controlled-substance compliance requirements;
FDA requirements for bioequivalence;
Labeling restrictions;
Trademark and trade-dress rights;
State cannabis and controlled-substance rules;
Contractual restrictions unrelated to the expired patent.

A generic capsule using sesame oil may have encountered formulation or listing issues during the patent’s term. Those issues no longer derive from Patent 6,703,418 itself.

How does Patent 6,703,418 compare with other cannabinoid patents?

Patent category	Typical protected subject matter	Relationship to 6,703,418
Compound patent	Novel cannabinoid molecule	6,703,418 is not primarily a compound patent
Composition patent	Specific excipients, ratios, or stability profile	6,703,418 has limited composition specificity
Formulation patent	Capsule, oral solution, patch, inhaler, or controlled release	6,703,418 covers use of forms, not necessarily their standalone composition
Method-of-use patent	Treatment of HIV wasting or appetite loss	This is the principal category
Manufacturing patent	Synthesis, purification, crystallization, or isolation	Not the principal subject
Device patent	Inhaler, transdermal system, or delivery apparatus	Not the principal subject
Regulatory exclusivity	FDA marketing protection	Separate from patent rights

Key Takeaways

U.S. Patent 6,703,418 covered delta-9-THC and dronabinol treatment for weight gain in symptomatic HIV patients.
Claim 1 was a broad method-of-use claim, limited by the HIV patient population and weight-gain objective.
Dependent claims covered oral administration, sesame-oil capsules, soft gelatin capsules, alternative routes, antiviral therapy, and 2.5 mg to 20 mg daily dosing.
The patent issued on March 9, 2004, and expired at approximately the 2020 patent-term endpoint.
The patent no longer blocks generic dronabinol capsules, oral solutions, or competing HIV-wasting treatments.
Dronabinol is regulated as a small molecule through the NDA and ANDA systems, not the biosimilar pathway.
Any current market barrier must come from a separate patent, regulatory exclusivity, manufacturing right, controlled-substance requirement, or commercial agreement.
The strongest historical validity issues concerned prior art, enablement across the broad dosage-form list, and the functional “sufficient to cause an increase in weight” limitation.

FAQs

Does Patent 6,703,418 cover all uses of Marinol?

No. It covers a defined HIV-related weight-gain method. It does not cover every Marinol use, including chemotherapy-induced nausea and vomiting.

Does a dronabinol manufacturer infringe by selling capsules with sesame oil?

Not solely because the capsules contain dronabinol and sesame oil. During the patent term, infringement would have required practice of the claimed HIV weight-gain method and satisfaction of the applicable capsule and administration limitations. The patent is now expired.

Does the patent cover cannabis-derived THC?

The claims recite delta-9-tetrahydrocannabinol. Whether a particular cannabis-derived product met the pharmaceutical-composition and regulatory limitations would have depended on its composition, labeling, and use. The patent’s expiration removes the current exclusionary issue.

Could a transdermal THC product have infringed the patent?

During the patent term, a transdermal THC product used to stimulate weight gain in a symptomatic HIV patient could have implicated claims 4, 5, or 11, subject to claim construction and proof of the claimed therapeutic use.

Is Patent 6,703,418 relevant to modern medical-cannabis products?

Only historically and technically. Modern products may involve different cannabinoids, delivery systems, manufacturing methods, or indications. Patent 6,703,418 itself is expired and does not currently restrict those products.

References

U.S. Patent No. 6,703,418. (2004). Use of tetrahydrocannabinol in the treatment of HIV wasting syndrome. United States Patent and Trademark Office.
U.S. Food and Drug Administration. (2023). Marinol (dronabinol) prescribing information. FDA.
U.S. Food and Drug Administration. (2023). Syndros (dronabinol) oral solution prescribing information. FDA.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.
United States Code, Title 35, §§ 154, 271. (2024). Patent term and infringement provisions. U.S. Government Publishing Office.

Details for Patent: 6,703,418

Summary for Patent: 6,703,418